141 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, operationalize and maintain corporate collaborations
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
manner and whether APHEXDA receives adequate reimbursement from third-party payors;
our ability to establish, manage, and maintain corporate … Medicare reimbursement for APHEXDA to transplant centers treating Medicare beneficiaries.
Out-Licensing of Motixafortide in Asia
In October 2023, we
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
the Centers for Medicare and Medicaid Services (CMS), ensuring that reimbursement for APHEXDA for Medicare and certain commercial payers will be separate from … to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, operationalize
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party
6-K
EX-99
1xo8657qj1ppwhp9
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
iife0vhri41l9r5
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
i5i0hbj7vqglsra8m
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-10.1
wlqco t232
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-99.1
cwbg5ml8b
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
kn49mv3i3e2 xb44
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
9g40vp3jvx8v31
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
y8xpu1ho
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
roxg5dwwcw 3by0r4f6z
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
egkeyje2xxpt6b
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
dn4n eujz
16 Feb 24
Current report (foreign)
7:07am
F-3
xkgyq7s5
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
icsnzbz
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
6mi7 8qlbpn
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am